ÐÒÔË·Éͧ¼Æ»®

The prizes were awarded at Helse Vest's research conference which took place in Stavanger at Sola Strand Hotel on Thursday 29 and Friday 30 October 2015.

Helga Salvesen's research group has done groundbreaking research on cervical cancer.

"It is great to receive this prize, and I am very happy for that. I'm glad to be able to share the joy with all the colleagues who are part of the research group, both at the university and at Haukeland University Hospital. I have many to thank for the work they have done, still I would particularly like to convey my gratitude to all the women who have contributed with samples and made it possible to do this research",ÌýsaysÌýHelga Salvesen in an interview to.​

Salvesen adds that the group has been given good working conditions to take the research further and to plan for even more projects, so that they could work both across health regions in Norway and cooperate with other countries.

Also read article in Bergens Tidende: Ìý(in Norwegian).

Ìý

Individualized treatment

In 2011, Salvesen received the Helse Vest Innovation Award together with Lars A. Akslen for a new technology that can provide uterine cancer patients better and more customized treatment. Since then, Salvesen and her research group have taken their research to clinical implementation, that is, the results of the research can be used to benefit the patients.

"We can provide better identification of patients with low risk of relapse, thereby potentially contributing to better quality of life by for example letting them avoid chemotherapy. We are now able to identify "mother tumors" in the woman and tumors with proliferation, and contribute to more individualized treatment", Salvesen explains.
Managing Director Herlof Nilssen at Helse Vest presented the award, which consists of 200,000 Norwegian Kroner and a work of art.

what the jury says about the awarding to Helga Salvesen (in Norwegian).

Ìý

Innovation Award to James Lorens

James Lorens received the Innovation Award for developing and improving treatment against breast cancer.ÌýHe has shown that good research can be successfully transferred to innovation and product development.

Lorens has, together with his research group, found that the AXL receptor tyrosine kinase plays a fundamental role in breast cancer. As a result of these findings it is possible to treat cancers that haveÌýreached an advanced stage, and inhibit cancer cells' ability to spread and become resistant to drugs.

Lorens has together withÌýÌýestablished the companyÌý, a company thatÌýis one of the nation's most important biotechnology initiatives in 2015. (Also read about BerGenBio receiving aÌý.)

Ìý

"This is a big surprise and I am very grateful for the award", says Lorens toÌý. "This is a great validation of the work we've done, and shows that investment and innovation is encouraged. It is possible to commercialize basic research, and this has happened relatively quickly. The patients are the ones who will benefit from the work we are doing. In a way you could say that we are taking the laboratory to the patients. It is easy to say but not so easy to actually do", Lorens explains.

Ìý

Supports the next generation

Lorens has no clear idea of what he would use the prize money to, but hope they can go to the next generation of researchers, so that they can go abroad and learn more."This award is not just for me. Many interdisciplinary collaborations, over several decades, have been part of making this possible. With private investors, we have been able to develop novel treatment. I hope that with this award we can be an inspiration to others", says the Innovation Award winner.

Ìýwhat the jury says about the awarding to James Lorens (in Norwegian).

Ìý

Congratulations to both!

Ìý

Ìý